7-(piperazin-1-yl)thiazolo[5,4-d]pyrimidin-5-ylamine hydrochloride | 1435953-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-(piperazin-1-yl)thiazolo[5,4-d]pyrimidin-5-ylamine hydrochloride
• 英文别名: 7-piperazin-1-yl-[1,3]thiazolo[5,4-d]pyrimidin-5-amine;hydrochloride
• CAS: 1435953-81-3
• 化学式: C₉H₁₂N₆S*ClH
• 分子量: 272.761
• InChiKey: GXZLEMJXPKUMFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7-(piperazin-1-yl)thiazolo[5,4-d]pyrimidin-5-ylamine hydrochloride 、 3-异氰酸吡啶 在 base (DIPEA or triethylamine) 作用下， 反应 4.0h， 生成 4-(5-aminothiazolo[5,4-d]pyrimidin-7-yl)-N-(3-pyridyl)-piperazine-1-carboxamide
  参考文献：
  名称：

  Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo

  摘要：

  The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4-d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIII beta. Evaluation of the series highlighted their poor solubility and unwanted off-target activities. A medicinal chemistry strategy was put in place to optimize physicochemical properties within the series, while maintaining potency and improving selectivity over other lipid kinases. Compound 22 was initially identified and profiled in vivo, before further modifications led to the discovery of 44 (UCB9608), a vastly more soluble, selective compound with improved metabolic stability and excellent pharmacokinetic profile. A co-crystal structure of 44 with PI4KIII beta was solved, confirming the binding mode of this class of inhibitor. The much-improved in vivo profile of 44 positions it as an ideal tool compound to further establish the link between PI4KIII beta inhibition and prolonged allogeneic organ engraftment, and suppression of immune responses in vivo.

  DOI：

  10.1021/acs.jmedchem.8b00521
• 作为产物：
  描述：

  7-chlorothiazolo[5,4-d]pyrimidin-5-amine 在 劳森试剂 、 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 7-(piperazin-1-yl)thiazolo[5,4-d]pyrimidin-5-ylamine hydrochloride
  参考文献：
  名称：

  Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo

  摘要：

  The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4-d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIII beta. Evaluation of the series highlighted their poor solubility and unwanted off-target activities. A medicinal chemistry strategy was put in place to optimize physicochemical properties within the series, while maintaining potency and improving selectivity over other lipid kinases. Compound 22 was initially identified and profiled in vivo, before further modifications led to the discovery of 44 (UCB9608), a vastly more soluble, selective compound with improved metabolic stability and excellent pharmacokinetic profile. A co-crystal structure of 44 with PI4KIII beta was solved, confirming the binding mode of this class of inhibitor. The much-improved in vivo profile of 44 positions it as an ideal tool compound to further establish the link between PI4KIII beta inhibition and prolonged allogeneic organ engraftment, and suppression of immune responses in vivo.

  DOI：

  10.1021/acs.jmedchem.8b00521

文献信息

• [EN] THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS THIAZOLO-PYRIMIDINE THÉRAPEUTIQUEMENT ACTIFS
  申请人：UCB PHARMA SA

  公开号：WO2013068458A1

  公开（公告）日：2013-05-16

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥。
• Therapeutically Active Thiazolo-Pyrimidine Derivatives
  申请人：UCB Pharma S.A.

  公开号：US20140315885A1

  公开（公告）日：2014-10-23

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥反应。
• THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES
  申请人：UCB Biopharma SPRL

  公开号：EP2776445B1

  公开（公告）日：2016-08-10
• US9096614B2
  申请人：——

  公开号：US9096614B2

  公开（公告）日：2015-08-04